MAPT and neurodegenerative disease: Studies have shown that a combination of different biomarkers (such as amyloid-PET along with measurement of p-tau in cerebrospinal fluid) can significantly increase diagnostic accuracy and enable differentiation between various subgroups of neurodegenerative diseases [69,70].